The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Shanghai Shenqi Pharmaceutical Investment Management Co Pretax Margin % Related Terms
Shanghai Shenqi Pharmaceutical Investment Management Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co Pretax Margin % Chart
Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co Pretax Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Pretax Margin % of 4.59% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. This is near median its historical median of 4.30. According to the industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #564 out of 956 companies in the Drug Manufacturers industry, placing it in the top 59%.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's Pretax Margin % too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current Pretax Margin % of 4.59% is near median its 10-year median of 4.30. The Drug Manufacturers industry median Pretax Margin % is 7.29. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 4.59% is 37% below this industry median. Based on the distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #564 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #564 out of 956 companies for Pretax Margin %. This places Shanghai Shenqi Pharmaceutical Investment Management Co in the lower half of its industry. The industry median Pretax Margin % is 7.29. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 4.59% is 37% below this benchmark. While the company's 10-year median is 4.30 vs. the industry median of 7.29, Shanghai Shenqi Pharmaceutical Investment Management Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shenqi Pharmaceutical Investment Management Co's current Pretax Margin % of 4.59% is 37% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shenqi Pharmaceutical Investment Management Co's current Pretax Margin % is 4.59%, which is near median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.44, compared to a current price of ¥4.82 — trading 11.4% below its estimated fair value. The current Pretax Margin % is 4.59%, which is near median its 10-year median of 4.30 and 37% below the Drug Manufacturers industry median of 7.29. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Pretax Margin % is 4.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued.
The current stock price of ¥4.82 is trading 11.4% below its estimated GF Value™ of ¥5.44.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.
Key valuation signals for SHSE:600613:
Pretax Margin %: 4.59% (near median its 10-year median of 4.30)
GF Value™: ¥5.44 vs. price of ¥4.82 (11.4% below fair value)
Industry Position: 37% below the Drug Manufacturers median (#564 of 956)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shenqi Pharmaceutical Investment Management Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
